# eye Insights Issue 02: Fueling a Revolution in Retinal Care ## expand\_more ![Eye Insights 2 Cover](/sites/g/files/omnuum9886/files/styles/hwp_1_1__100x100_scale/public/eye/files/eyeinsights2cover.png?itok=m6GvZGHr) How biomedical breakthroughs in anti-VEGF research have changed how we diagnose, treat, and save vision for patients with retinal disease.Sort - Annually, 500,000 ophthalmic patients in the United States and over 1 million worldwide are treated with all anti-VEGF agents combined. - Anti-VEGF treatments have been shown to halt vision loss in more than 90 percent of patients with AMD and to improve vision in one-third. - VEGF inhibitors hold potential for a growing list of indications, including neovascular glaucoma and retinopathy of prematurity. - VEGF inhibitors have been used experimentally to treat over 50 ocular diseases. ***Inside:*** - **[2014 António Champalimaud Vision Award](/eyeinsights/2015-january/2014-antonio-champalimaud-vision-award)** - **[AMD Treatment Guidelines](/eyeinsights/2015-january/age-related-macular-degeneration-amd)** - **[Fueling a Revolution in Retinal Care](/eyeinsights/2015-january/fueling-revolution-retinal-care)** - **[Novel Strategies Set the Stage for Next Generation Therapies](/eyeinsights/2015-january/novel-strategies-set-stage-next-generation-therapies)** *Editor-in-Chief: Joan W. Miller, MD, FARVO* *Managing Editor: Matthew F. Gardiner, MD* *Communications Director: Suzanne Ward* *Scientific Communications Manager: Wendy Chao, PhD* *Clinical Advisory Group: Carolyn E. Kloek, MD, Deeba Husain, MD, Ankoor S. Shah, MD, PhD, Angela V. Turalba, MD* [Browse all issues >>](/documents/newsletter/eye-insights) | Email: --- Attachments- [ picture\_as\_pdf eye Insights 2 PDF ](/sites/g/files/omnuum9886/files/eye/files/eyeinsights-jan-2015.pdf) --- See also:- [ eye Insights ](/newsletter/eye-insights)